ddb personal page - To The Moon

ddb

ddb

No personal profile

104Follow

5Followers

0Topic

0Badge

2022-01-04

Nice

5 Stocks To Watch For January 4, 2022

2022-01-20

Gogog

Alcoa Stock Gained 2.5% in Premarket Trading

2022-01-03

Nice

Toplines Before US Market Open on Monday

2022-01-07

Great

Could Ocugen Become the Next Moderna?

2022-01-18

Gofogo

Microsoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln

2022-01-04

Tesla up

Cathie Wood Continues Booking Profit In Tesla As Stock Shoots Up, Loads Up On These 2 Stocks Instead

2022-01-06

Like

Sorry, the original content has been removed

2022-01-06

Like pls

BRIEF-U.S. CDC Says Delivered 618,076,045 Doses Of Covid-19 Vaccine As Of Jan 5

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575010414156273","uuid":"3575010414156273","gmtCreate":1611916413362,"gmtModify":1635873241314,"name":"ddb","pinyin":"ddb","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":104,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9004428411,"gmtCreate":1642670175359,"gmtModify":1676533733937,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Gogog","listText":"Gogog","text":"Gogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004428411","repostId":"1133471049","repostType":4,"isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004352400,"gmtCreate":1642515809202,"gmtModify":1676533717570,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Gofogo","listText":"Gofogo","text":"Gofogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004352400","repostId":"1149966362","repostType":4,"repost":{"id":"1149966362","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642512559,"share":"https://ttm.financial/m/news/1149966362?lang=&edition=fundamental","pubTime":"2022-01-18 21:29","market":"us","language":"en","title":"Microsoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=1149966362","media":"Tiger Newspress","summary":"Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game develop","content":"<html><head></head><body><p>Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.</p><p>Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.</p><p>Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.</p><p>The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.</p><p>The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-18 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.</p><p>Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.</p><p>Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.</p><p>The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.</p><p>The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","ATVI":"动视暴雪"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149966362","content_text":"Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.","news_type":1},"isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006024471,"gmtCreate":1641560793996,"gmtModify":1676533629189,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006024471","repostId":"2201121648","repostType":2,"repost":{"id":"2201121648","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","BK4550":"红杉资本持仓","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4563":"昨日强势股","BK4548":"巴美列捷福持仓","PFE":"辉瑞","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008509074,"gmtCreate":1641476369206,"gmtModify":1676533618874,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008509074","repostId":"2201525399","repostType":2,"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008500436,"gmtCreate":1641476359718,"gmtModify":1676533618876,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008500436","repostId":"2201525399","repostType":2,"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001409822,"gmtCreate":1641291679490,"gmtModify":1676533593639,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Tesla up","listText":"Tesla up","text":"Tesla up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001409822","repostId":"1124443897","repostType":4,"isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001409158,"gmtCreate":1641291658742,"gmtModify":1676533593617,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001409158","repostId":"1127361669","repostType":4,"isVote":1,"tweetType":1,"viewCount":699,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001815986,"gmtCreate":1641215669081,"gmtModify":1676533583620,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001815986","repostId":"1186246259","repostType":4,"isVote":1,"tweetType":1,"viewCount":903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9001409158,"gmtCreate":1641291658742,"gmtModify":1676533593617,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001409158","repostId":"1127361669","repostType":4,"repost":{"id":"1127361669","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1641291181,"share":"https://ttm.financial/m/news/1127361669?lang=&edition=fundamental","pubTime":"2022-01-04 18:13","market":"us","language":"en","title":"5 Stocks To Watch For January 4, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1127361669","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings,","content":"<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For January 4, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For January 4, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-04 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ITCI":"Intra-Cellular Therapies Inc.","ASGN":"盎塞","MLKN":"MillerKnoll","JAZZ":"爵士制药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127361669","content_text":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings, Inc. to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.ASGN Incorporated reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.Analysts are expecting MillerKnoll, Inc to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.Intra-Cellular Therapies, Inc. reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.Jazz Pharmaceuticals plc reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":699,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004428411,"gmtCreate":1642670175359,"gmtModify":1676533733937,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Gogog","listText":"Gogog","text":"Gogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004428411","repostId":"1133471049","repostType":4,"repost":{"id":"1133471049","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642669664,"share":"https://ttm.financial/m/news/1133471049?lang=&edition=fundamental","pubTime":"2022-01-20 17:07","market":"us","language":"en","title":"Alcoa Stock Gained 2.5% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133471049","media":"Tiger Newspress","summary":"Alcoa stock gained 2.5% in premarket trading after the company reported strong fourth-quarter result","content":"<html><head></head><body><p>Alcoa stock gained 2.5% in premarket trading after the company reported strong fourth-quarter results.</p><p><img src=\"https://static.tigerbbs.com/e7b12eee20f8fbbc77a68f4801a9f709\" tg-width=\"843\" tg-height=\"617\" referrerpolicy=\"no-referrer\"/></p><p>There is plenty to like from the report: Results look solid and financial guidance for the first quarter of 2022 is strong.</p><p>Alcoa reported $896 million in Ebitda—short for earnings before interest, taxes, depreciation, and amortization—right in line with Wall Street estimates. It posted adjusted earnings of $2.50 a share from $3.3 billion in sales; Wall Street was looking for $1.93 in per-share earnings from $3.3 billion in sales.</p><p>The fourth-quarter 2021 results are a sharp improvement from a year ago, when Alcoa earned $361 million in Ebitda and 26 cents a share from $2.4 billion in sales.</p><p>Commodity aluminum prices are up roughly 50% over the past year. That’s a powerful tailwind for Alcoa results. Higher aluminum prices are also a powerful tailwind for the stock. Alcoa shares have gained about 160% over the past 12 months.</p><p>Management appeared pleased with the fourth-quarter and full-year performance. “We had a transformative year in 2021; we posted our highest ever annual net income, returned cash to our stockholders and significantly reduced our debt and pension obligations,” said CEO Roy Harvey in the company’s news release.</p><p>Alcoa paid back about $1.3 billion in bonds during 2021, added $500 million to the company’s U.S. pension plans, and spent $150 million buying back stock.</p><p>Looking ahead, Alcoa expects first-quarter results to come close to the fourth-quarter figures. That’s better than analysts are projecting. Wall Street currently expects $870 million in Ebitda and $1.63 in per-share earnings from $3.2 billion in sales for the first quarter.</p><p>For all of 2022, analysts project $3.2 billion in Ebitda and $6.52 in per-share earnings from $13.1 billion in sales. Of course, commodity prices will have a lot to say about exactly how Alcoa’s year turns out.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcoa Stock Gained 2.5% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcoa Stock Gained 2.5% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-20 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alcoa stock gained 2.5% in premarket trading after the company reported strong fourth-quarter results.</p><p><img src=\"https://static.tigerbbs.com/e7b12eee20f8fbbc77a68f4801a9f709\" tg-width=\"843\" tg-height=\"617\" referrerpolicy=\"no-referrer\"/></p><p>There is plenty to like from the report: Results look solid and financial guidance for the first quarter of 2022 is strong.</p><p>Alcoa reported $896 million in Ebitda—short for earnings before interest, taxes, depreciation, and amortization—right in line with Wall Street estimates. It posted adjusted earnings of $2.50 a share from $3.3 billion in sales; Wall Street was looking for $1.93 in per-share earnings from $3.3 billion in sales.</p><p>The fourth-quarter 2021 results are a sharp improvement from a year ago, when Alcoa earned $361 million in Ebitda and 26 cents a share from $2.4 billion in sales.</p><p>Commodity aluminum prices are up roughly 50% over the past year. That’s a powerful tailwind for Alcoa results. Higher aluminum prices are also a powerful tailwind for the stock. Alcoa shares have gained about 160% over the past 12 months.</p><p>Management appeared pleased with the fourth-quarter and full-year performance. “We had a transformative year in 2021; we posted our highest ever annual net income, returned cash to our stockholders and significantly reduced our debt and pension obligations,” said CEO Roy Harvey in the company’s news release.</p><p>Alcoa paid back about $1.3 billion in bonds during 2021, added $500 million to the company’s U.S. pension plans, and spent $150 million buying back stock.</p><p>Looking ahead, Alcoa expects first-quarter results to come close to the fourth-quarter figures. That’s better than analysts are projecting. Wall Street currently expects $870 million in Ebitda and $1.63 in per-share earnings from $3.2 billion in sales for the first quarter.</p><p>For all of 2022, analysts project $3.2 billion in Ebitda and $6.52 in per-share earnings from $13.1 billion in sales. Of course, commodity prices will have a lot to say about exactly how Alcoa’s year turns out.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AA":"美国铝业"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133471049","content_text":"Alcoa stock gained 2.5% in premarket trading after the company reported strong fourth-quarter results.There is plenty to like from the report: Results look solid and financial guidance for the first quarter of 2022 is strong.Alcoa reported $896 million in Ebitda—short for earnings before interest, taxes, depreciation, and amortization—right in line with Wall Street estimates. It posted adjusted earnings of $2.50 a share from $3.3 billion in sales; Wall Street was looking for $1.93 in per-share earnings from $3.3 billion in sales.The fourth-quarter 2021 results are a sharp improvement from a year ago, when Alcoa earned $361 million in Ebitda and 26 cents a share from $2.4 billion in sales.Commodity aluminum prices are up roughly 50% over the past year. That’s a powerful tailwind for Alcoa results. Higher aluminum prices are also a powerful tailwind for the stock. Alcoa shares have gained about 160% over the past 12 months.Management appeared pleased with the fourth-quarter and full-year performance. “We had a transformative year in 2021; we posted our highest ever annual net income, returned cash to our stockholders and significantly reduced our debt and pension obligations,” said CEO Roy Harvey in the company’s news release.Alcoa paid back about $1.3 billion in bonds during 2021, added $500 million to the company’s U.S. pension plans, and spent $150 million buying back stock.Looking ahead, Alcoa expects first-quarter results to come close to the fourth-quarter figures. That’s better than analysts are projecting. Wall Street currently expects $870 million in Ebitda and $1.63 in per-share earnings from $3.2 billion in sales for the first quarter.For all of 2022, analysts project $3.2 billion in Ebitda and $6.52 in per-share earnings from $13.1 billion in sales. Of course, commodity prices will have a lot to say about exactly how Alcoa’s year turns out.","news_type":1},"isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001815986,"gmtCreate":1641215669081,"gmtModify":1676533583620,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001815986","repostId":"1186246259","repostType":4,"repost":{"id":"1186246259","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641214924,"share":"https://ttm.financial/m/news/1186246259?lang=&edition=fundamental","pubTime":"2022-01-03 21:02","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1186246259","media":"Tiger Newspress","summary":"U.S. stock index futures are starting the year with some more champagne.At 8:00 a.m. ET, Dow e-minis","content":"<html><head></head><body><p>U.S. stock index futures are starting the year with some more champagne.</p><p>At 8:00 a.m. ET, Dow e-minis were up 162 points, or 0.45%, S&amp;P 500 e-minis were up 26.75 points, or 0.56%, and Nasdaq 100 e-minis were up 113 points, or 0.69%.<img src=\"https://static.tigerbbs.com/10365f59893373bad1fdc498f5ca24b6\" tg-width=\"1080\" tg-height=\"359\" width=\"100%\" height=\"auto\"/>It follows a strong 2021 for each of the indices despite fears of inflation, tighter monetary policy, business disruptions and new COVID-19 variants. Investors seemed to focus on the bright spots of the macroeconomic picture instead, such as increased consumer spending, hiring ramp-ups and solid corporate earnings growth.</p><p><b>Stocks making the biggest moves premarket: </b></p><p><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> </b>– <a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> surged 7.4% in the premarket following news thatit delivered 308,600 vehiclesduring the fourth quarter, well above the consensus estimate of 263,026. The quarter’s deliveries were 70% above year-ago levels and about 30% higher than the prior quarter.</p><p><b><a href=\"https://laohu8.com/S/MCD\">McDonald&#39;s</a></b> – McDonald’s was upgraded to “overweight” from “neutral” at Piper Sandler, which points to the restaurant chain’s ability to deliver on increasing preferences for drive-through and elevated demand for chicken and hamburger offerings. McDonald’s rose 1.1% in premarket trading.</p><p><b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> – <a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a>  gained 2.2% in the premarket after the China-based electric vehicle maker reported December deliveries of 10,489 vehicles, up 50% from December 2020.</p><p><b><a href=\"https://laohu8.com/S/XPEV\">XPeng Inc.</a></b> – <a href=\"https://laohu8.com/S/XPEV\">XPeng Inc.</a> – another China-based EV maker – rallied 2.5% in premarket trading as it, too, exceeded estimates by delivering 16,000 vehicles last month. That was up 181% from a year earlier.</p><p><b><a href=\"https://laohu8.com/S/LI\">Li Auto</a></b> – <a href=\"https://laohu8.com/S/LI\">Li Auto</a> delivered 14,087 electric vehicles in December, a gain of 130% year-over-year, matching its fellow China-based EV makers. Li Auto shares added 2.8% in premarket action.</p><p><b><a href=\"https://laohu8.com/S/ODP\">Office Depot</a></b> – <a href=\"https://laohu8.com/S/ODP\">Office Depot</a> jumped 3.1% in premarket trading after it announced the sale of its CompuCom unit in a deal valued at up to $305 million. The Office Depot and OfficeMax parent also added $200 million to its stock buyback program.</p><p><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> – <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> gained 1.9% in the premarket, following a BMO upgrade to “outperform” from “market perform” based on the payment service’s current valuation.</p><p><b><a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a></b> – The bank’s shares added 1.4% in premarket trading after Barclays upgraded Wells Fargo to “overweight” from “equal weight.” Barclays expects banks to outperform the market in 2022 as net interest margins improve off historic lows.</p><p><b><a href=\"https://laohu8.com/S/AMD\">AMD</a></b> – The chipmaker was one of several semiconductor stocks named as “top picks” at Goldman Sachs, which said AMD is among the companies that will see continued strength as sector outperformance becomes more muted in 2022. AMD rose 1.2% in the premarket. The other semiconductor “top picks” were Marvell Technology(MRVL), up 1.2% in premarket trading, and Micron Technology(MU), up 0.9%.</p><p><b><a href=\"https://laohu8.com/S/ELY\">Callaway Golf</a></b> – The golf equipment maker was named a “top pick” at Compass Point, which said Callaway is on an “operational roll” with growth expected across all its businesses in 2022. Callaway added 1.9% in the premarket.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-03 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures are starting the year with some more champagne.</p><p>At 8:00 a.m. ET, Dow e-minis were up 162 points, or 0.45%, S&amp;P 500 e-minis were up 26.75 points, or 0.56%, and Nasdaq 100 e-minis were up 113 points, or 0.69%.<img src=\"https://static.tigerbbs.com/10365f59893373bad1fdc498f5ca24b6\" tg-width=\"1080\" tg-height=\"359\" width=\"100%\" height=\"auto\"/>It follows a strong 2021 for each of the indices despite fears of inflation, tighter monetary policy, business disruptions and new COVID-19 variants. Investors seemed to focus on the bright spots of the macroeconomic picture instead, such as increased consumer spending, hiring ramp-ups and solid corporate earnings growth.</p><p><b>Stocks making the biggest moves premarket: </b></p><p><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> </b>– <a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a> surged 7.4% in the premarket following news thatit delivered 308,600 vehiclesduring the fourth quarter, well above the consensus estimate of 263,026. The quarter’s deliveries were 70% above year-ago levels and about 30% higher than the prior quarter.</p><p><b><a href=\"https://laohu8.com/S/MCD\">McDonald&#39;s</a></b> – McDonald’s was upgraded to “overweight” from “neutral” at Piper Sandler, which points to the restaurant chain’s ability to deliver on increasing preferences for drive-through and elevated demand for chicken and hamburger offerings. McDonald’s rose 1.1% in premarket trading.</p><p><b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> – <a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a>  gained 2.2% in the premarket after the China-based electric vehicle maker reported December deliveries of 10,489 vehicles, up 50% from December 2020.</p><p><b><a href=\"https://laohu8.com/S/XPEV\">XPeng Inc.</a></b> – <a href=\"https://laohu8.com/S/XPEV\">XPeng Inc.</a> – another China-based EV maker – rallied 2.5% in premarket trading as it, too, exceeded estimates by delivering 16,000 vehicles last month. That was up 181% from a year earlier.</p><p><b><a href=\"https://laohu8.com/S/LI\">Li Auto</a></b> – <a href=\"https://laohu8.com/S/LI\">Li Auto</a> delivered 14,087 electric vehicles in December, a gain of 130% year-over-year, matching its fellow China-based EV makers. Li Auto shares added 2.8% in premarket action.</p><p><b><a href=\"https://laohu8.com/S/ODP\">Office Depot</a></b> – <a href=\"https://laohu8.com/S/ODP\">Office Depot</a> jumped 3.1% in premarket trading after it announced the sale of its CompuCom unit in a deal valued at up to $305 million. The Office Depot and OfficeMax parent also added $200 million to its stock buyback program.</p><p><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> – <a href=\"https://laohu8.com/S/PYPL\">PayPal</a> gained 1.9% in the premarket, following a BMO upgrade to “outperform” from “market perform” based on the payment service’s current valuation.</p><p><b><a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a></b> – The bank’s shares added 1.4% in premarket trading after Barclays upgraded Wells Fargo to “overweight” from “equal weight.” Barclays expects banks to outperform the market in 2022 as net interest margins improve off historic lows.</p><p><b><a href=\"https://laohu8.com/S/AMD\">AMD</a></b> – The chipmaker was one of several semiconductor stocks named as “top picks” at Goldman Sachs, which said AMD is among the companies that will see continued strength as sector outperformance becomes more muted in 2022. AMD rose 1.2% in the premarket. The other semiconductor “top picks” were Marvell Technology(MRVL), up 1.2% in premarket trading, and Micron Technology(MU), up 0.9%.</p><p><b><a href=\"https://laohu8.com/S/ELY\">Callaway Golf</a></b> – The golf equipment maker was named a “top pick” at Compass Point, which said Callaway is on an “operational roll” with growth expected across all its businesses in 2022. Callaway added 1.9% in the premarket.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","PYPL":"PayPal",".SPX":"S&P 500 Index","WFC":"富国银行","ODP":"欧迪办公","MCD":"麦当劳","AMD":"美国超微公司",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","XPEV":"小鹏汽车","NIO":"蔚来","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186246259","content_text":"U.S. stock index futures are starting the year with some more champagne.At 8:00 a.m. ET, Dow e-minis were up 162 points, or 0.45%, S&P 500 e-minis were up 26.75 points, or 0.56%, and Nasdaq 100 e-minis were up 113 points, or 0.69%.It follows a strong 2021 for each of the indices despite fears of inflation, tighter monetary policy, business disruptions and new COVID-19 variants. Investors seemed to focus on the bright spots of the macroeconomic picture instead, such as increased consumer spending, hiring ramp-ups and solid corporate earnings growth.Stocks making the biggest moves premarket: Tesla Motors – Tesla Motors surged 7.4% in the premarket following news thatit delivered 308,600 vehiclesduring the fourth quarter, well above the consensus estimate of 263,026. The quarter’s deliveries were 70% above year-ago levels and about 30% higher than the prior quarter.McDonald's – McDonald’s was upgraded to “overweight” from “neutral” at Piper Sandler, which points to the restaurant chain’s ability to deliver on increasing preferences for drive-through and elevated demand for chicken and hamburger offerings. McDonald’s rose 1.1% in premarket trading.NIO Inc. – NIO Inc.  gained 2.2% in the premarket after the China-based electric vehicle maker reported December deliveries of 10,489 vehicles, up 50% from December 2020.XPeng Inc. – XPeng Inc. – another China-based EV maker – rallied 2.5% in premarket trading as it, too, exceeded estimates by delivering 16,000 vehicles last month. That was up 181% from a year earlier.Li Auto – Li Auto delivered 14,087 electric vehicles in December, a gain of 130% year-over-year, matching its fellow China-based EV makers. Li Auto shares added 2.8% in premarket action.Office Depot – Office Depot jumped 3.1% in premarket trading after it announced the sale of its CompuCom unit in a deal valued at up to $305 million. The Office Depot and OfficeMax parent also added $200 million to its stock buyback program.PayPal – PayPal gained 1.9% in the premarket, following a BMO upgrade to “outperform” from “market perform” based on the payment service’s current valuation.Wells Fargo – The bank’s shares added 1.4% in premarket trading after Barclays upgraded Wells Fargo to “overweight” from “equal weight.” Barclays expects banks to outperform the market in 2022 as net interest margins improve off historic lows.AMD – The chipmaker was one of several semiconductor stocks named as “top picks” at Goldman Sachs, which said AMD is among the companies that will see continued strength as sector outperformance becomes more muted in 2022. AMD rose 1.2% in the premarket. The other semiconductor “top picks” were Marvell Technology(MRVL), up 1.2% in premarket trading, and Micron Technology(MU), up 0.9%.Callaway Golf – The golf equipment maker was named a “top pick” at Compass Point, which said Callaway is on an “operational roll” with growth expected across all its businesses in 2022. Callaway added 1.9% in the premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006024471,"gmtCreate":1641560793996,"gmtModify":1676533629189,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006024471","repostId":"2201121648","repostType":2,"repost":{"id":"2201121648","pubTimestamp":1641555582,"share":"https://ttm.financial/m/news/2201121648?lang=&edition=fundamental","pubTime":"2022-01-07 19:39","market":"us","language":"en","title":"Could Ocugen Become the Next Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201121648","media":"Motley Fool","summary":"Ocugen faces a few major challenges.","content":"<html><head></head><body><p><b>Ocugen </b>(NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say &#34;surprise&#34; because the biotech&#39;s specialty isn&#39;t vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.</p><p>But Ocugen signed a deal with India&#39;s Bharat Biotech for the U.S. co-commercialization rights of the company&#39;s close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.</p><p>Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I&#39;m talking about vaccine-leader <b>Moderna</b> (NASDAQ:MRNA). The company&#39;s shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it&#39;s reasonable to ask: Could Ocugen follow in Moderna&#39;s footsteps?</p><p><img src=\"https://static.tigerbbs.com/5bd5599367557230d53e4f73290cc836\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Where Ocugen stands now</h2><p>Let&#39;s take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn&#39;t add money to Ocugen&#39;s coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.</p><p>Ocugen&#39;s shares have climbed from time to time on positive Covaxin trial data. The World Health Organization&#39;s addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don&#39;t bring Covaxin any closer to commercialization in the U.S. or Canada, and what&#39;s most important for Ocugen is to bring Covaxin to market -- and generate revenue.</p><p>So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with <b>Pfizer</b> and Moderna vaccines. That means it will be difficult to carve out market share. Still, there&#39;s a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the &#34;mixing and matching&#34; of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it&#39;s eventually approved).</p><p>I used the word &#34;approved&#34; above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.</p><h2>Trial on hold</h2><p>But the bad news doesn&#39;t stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can&#39;t start until Ocugen resolves questions or concerns the FDA has about the trial.</p><p>Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven&#39;t yet issued a decision.</p><p>The problem with Ocugen isn&#39;t the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it&#39;s extremely late to market, it may be difficult to generate significant revenue.</p><h2>The new Moderna?</h2><p>Let&#39;s get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.</p><p>These are two key reasons for Moderna&#39;s success today, and they&#39;re the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn&#39;t yet brought a candidate into clinical trials.</p><p>Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it&#39;s unclear when Covaxin will make it to market and how it can carve out much market share.</p><p>Ocugen&#39;s other programs are too early stage to bring in revenue any time soon. That&#39;s why I expect more volatility from the company. And it&#39;s unlikely it will follow in the footsteps of bigger biotech rival Moderna.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Ocugen Become the Next Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Ocugen Become the Next Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","BK4550":"红杉资本持仓","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4563":"昨日强势股","BK4548":"巴美列捷福持仓","PFE":"辉瑞","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/07/could-ocugen-become-the-next-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201121648","content_text":"Ocugen (NASDAQ:OCGN) became a surprise entrant in the coronavirus vaccine race last year. I say \"surprise\" because the biotech's specialty isn't vaccines or infectious diseases. Its focus is on gene therapy for eye diseases.But Ocugen signed a deal with India's Bharat Biotech for the U.S. co-commercialization rights of the company's close-to-market vaccine candidate Covaxin -- and investors cheered. In fact, all this interest propelled the stock to a 149% gain last year. And at its highest point, it rose more than 750%.Eye-popping share gains and a potential coronavirus vaccine may make us think of another biotech company. I'm talking about vaccine-leader Moderna (NASDAQ:MRNA). The company's shares soared 434% in 2020 as it developed and then commercialized a vaccine. The shares extended gains last year, and Moderna generated billions of dollars in vaccine revenue. Today, it's reasonable to ask: Could Ocugen follow in Moderna's footsteps?Image source: Getty Images.Where Ocugen stands nowLet's take a look at some background information on Ocugen -- and where the company stands now. Bharat Biotech has commercialized Covaxin in India and about a dozen other countries. But that doesn't add money to Ocugen's coffers. Ocugen holds co-commercialization rights in the U.S. and Canada only. The company would keep 45% of profits in those countries.Ocugen's shares have climbed from time to time on positive Covaxin trial data. The World Health Organization's addition of Covaxin to its emergency-use list also triggered optimism. These elements are positive because they support the idea that Covaxin is a safe and efficacious product. But they don't bring Covaxin any closer to commercialization in the U.S. or Canada, and what's most important for Ocugen is to bring Covaxin to market -- and generate revenue.So far, Ocugen faces some significant hurdles. First, the U.S. and Canada already have vaccinated large percentages of their populations with Pfizer and Moderna vaccines. That means it will be difficult to carve out market share. Still, there's a bit of good news: The U.S. Food and Drug Administration (FDA) has authorized the \"mixing and matching\" of boosters, so if you got the Pfizer primary series, for instance, you could get a Covaxin booster (if it's eventually approved).I used the word \"approved\" above because Ocugen is aiming for full approval -- not Emergency Use Authorization (EUA). And this represents another one of the hurdles. The FDA advised Ocugen last spring to opt for the traditional approval path rather than the EUA one. This means a review time of six to 10 months, versus a few weeks for an EUA.Trial on holdBut the bad news doesn't stop there. Ocugen planned on launching a new clinical trial for Covaxin to support its regulatory request. In November, however, the FDA issued a clinical hold on the request. That means the trial can't start until Ocugen resolves questions or concerns the FDA has about the trial.Ocugen submitted Covaxin to Canadian regulators in the second quarter of last year. They haven't yet issued a decision.The problem with Ocugen isn't the quality of the vaccine. Data from trials in India have been positive. The real uncertainty is if and when Covaxin will reach the U.S. and Canadian markets. And if it's extremely late to market, it may be difficult to generate significant revenue.The new Moderna?Let's get back to our Ocugen/Moderna comparison. They both have vaccine products backed by strong data. But Moderna quickly brought its vaccine from development to commercialization. And Moderna benefits from sales of its vaccine worldwide -- not just in two countries.These are two key reasons for Moderna's success today, and they're the two key elements missing from the Ocugen story. Moderna also has a pipeline with many late-stage programs, but Ocugen hasn't yet brought a candidate into clinical trials.Ocugen shares may gain on any positive Covaxin news in the coming weeks or months. But as mentioned above, it's unclear when Covaxin will make it to market and how it can carve out much market share.Ocugen's other programs are too early stage to bring in revenue any time soon. That's why I expect more volatility from the company. And it's unlikely it will follow in the footsteps of bigger biotech rival Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004352400,"gmtCreate":1642515809202,"gmtModify":1676533717570,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Gofogo","listText":"Gofogo","text":"Gofogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004352400","repostId":"1149966362","repostType":4,"repost":{"id":"1149966362","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642512559,"share":"https://ttm.financial/m/news/1149966362?lang=&edition=fundamental","pubTime":"2022-01-18 21:29","market":"us","language":"en","title":"Microsoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=1149966362","media":"Tiger Newspress","summary":"Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game develop","content":"<html><head></head><body><p>Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.</p><p>Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.</p><p>Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.</p><p>The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.</p><p>The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to acquire Activision Blizzard in all-cash deal valued at $68.7 bln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-18 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.</p><p>Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.</p><p>Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.</p><p>The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.</p><p>The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","ATVI":"动视暴雪"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149966362","content_text":"Today, Microsoft Corp. announced plans to acquire Activision Blizzard Inc., a leader in game development and interactive entertainment content publisher. This acquisition will accelerate the growth in Microsoft’s gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse.Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash. When the transaction closes, Microsoft will become the world’s third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like “Warcraft,” “Diablo,” “Overwatch,” “Call of Duty” and “Candy Crush,” in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees.Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company’s culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming.The acquisition also bolsters Microsoft’s Game Pass portfolio with plans to launch Activision Blizzard games into Game Pass, which has reached a new milestone of over 25 million subscribers. With Activision Blizzard’s nearly 400 million monthly active players in 190 countries and three billion-dollar franchises, this acquisition will make Game Pass one of the most compelling and diverse lineups of gaming content in the industry. Upon close, Microsoft will have 30 internal game development studios, along with additional publishing and esports production capabilities.The transaction is subject to customary closing conditions and completion of regulatory review and Activision Blizzard’s shareholder approval. The deal is expected to close in fiscal year 2023 and will be accretive to non-GAAP earnings per share upon close. The transaction has been approved by the boards of directors of both Microsoft and Activision Blizzard.","news_type":1},"isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001409822,"gmtCreate":1641291679490,"gmtModify":1676533593639,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Tesla up","listText":"Tesla up","text":"Tesla up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001409822","repostId":"1124443897","repostType":4,"repost":{"id":"1124443897","pubTimestamp":1641289590,"share":"https://ttm.financial/m/news/1124443897?lang=&edition=fundamental","pubTime":"2022-01-04 17:46","market":"us","language":"en","title":"Cathie Wood Continues Booking Profit In Tesla As Stock Shoots Up, Loads Up On These 2 Stocks Instead","url":"https://stock-news.laohu8.com/highlight/detail?id=1124443897","media":"Benzinga","summary":"Cathie Wood’sArk Investment Management on Monday sold more shares in Tesla Inc(NASDAQ:TSLA), startin","content":"<html><head></head><body><p><b>Cathie Wood</b>’s<b>Ark Investment Management</b> on Monday sold more shares in <b>Tesla Inc</b>(NASDAQ:TSLA), starting the new year with more profit booking in the electric vehicle stock as it jumped higher after reporting fourth-quarter delivery volumes that far surpassed expectations.</p><p>The popular asset management firm sold 39,262 shares — estimated to be worth $47 million — in Tesla.</p><p>The <b>Elon Musk</b>-led company’s stock soared 13.5% on Monday to close at $1,199.8 a share. The stock rose about 50% in 2021.</p><p>Wood’s firm has exposure in Tesla via three of its exchange-traded funds — the <b>Ark Innovation ETF</b>(NYSE:ARKK), the <b>Ark Autonomous Technology &amp; Robotics ETF</b>(NYSE:ARKQ) and the <b>Ark Next Generation Internet ETF</b>(NYSE:ARKW).</p><p>The three ETFs held about 1.75 million shares worth $1.84 billion in Tesla, prior to Monday’s trade.</p><p>Tesla on Sunday smashed fourth-quarter delivery records, posting its biggest quarterly and full-year delivery volume.</p><p>A Tesla super-bull, Wood has long favored the Musk-led company and set a $3,000 price target for the electric vehicle stock for 2025.</p><p>The St. Petersburg, Florida-based Ark has recently also begun buying shares in the U.S.-listed Chinese electric vehicle maker <b>Xpeng Inc</b>(NYSE:XPEV).</p><p>Here are some other key Ark Invest trades from Monday:</p><ul><li>Bought 442,456 shares — estimated to be worth $8.2 million — in <b>Palantir Technologies Inc</b>(NYSE:PLTR). Shares of the Peter Thiel-founded data company closed 1.8% higher at $18.5 a share.</li><li>Sold 359,577 shares — estimated to be worth $15.3 million — in <b>Twitter Inc</b>(NYSE:TWTR). The micro-blogging company’s stock closed 1.3% lower at $42.7 a share.</li><li>Bought 345,771 shares — estimated to be worth $6.4 million — in <b>Robinhood</b> <b>Markets Inc</b>(NASDAQ:HOOD). Shares of the commission-free trading app that deals in stocks, exchange-traded funds and cryptocurrencies closed 3.8% higher at $18.4 a share.</li></ul></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Continues Booking Profit In Tesla As Stock Shoots Up, Loads Up On These 2 Stocks Instead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Continues Booking Profit In Tesla As Stock Shoots Up, Loads Up On These 2 Stocks Instead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-04 17:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/long-ideas/22/01/24873551/cathie-wood-continues-booking-profit-in-tesla-as-stock-shoots-up-loads-up-on-these-2-sto><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood’sArk Investment Management on Monday sold more shares in Tesla Inc(NASDAQ:TSLA), starting the new year with more profit booking in the electric vehicle stock as it jumped higher after ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/22/01/24873551/cathie-wood-continues-booking-profit-in-tesla-as-stock-shoots-up-loads-up-on-these-2-sto\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HOOD":"Robinhood","TSLA":"特斯拉","PLTR":"Palantir Technologies Inc.","TWTR":"Twitter"},"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/22/01/24873551/cathie-wood-continues-booking-profit-in-tesla-as-stock-shoots-up-loads-up-on-these-2-sto","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124443897","content_text":"Cathie Wood’sArk Investment Management on Monday sold more shares in Tesla Inc(NASDAQ:TSLA), starting the new year with more profit booking in the electric vehicle stock as it jumped higher after reporting fourth-quarter delivery volumes that far surpassed expectations.The popular asset management firm sold 39,262 shares — estimated to be worth $47 million — in Tesla.The Elon Musk-led company’s stock soared 13.5% on Monday to close at $1,199.8 a share. The stock rose about 50% in 2021.Wood’s firm has exposure in Tesla via three of its exchange-traded funds — the Ark Innovation ETF(NYSE:ARKK), the Ark Autonomous Technology & Robotics ETF(NYSE:ARKQ) and the Ark Next Generation Internet ETF(NYSE:ARKW).The three ETFs held about 1.75 million shares worth $1.84 billion in Tesla, prior to Monday’s trade.Tesla on Sunday smashed fourth-quarter delivery records, posting its biggest quarterly and full-year delivery volume.A Tesla super-bull, Wood has long favored the Musk-led company and set a $3,000 price target for the electric vehicle stock for 2025.The St. Petersburg, Florida-based Ark has recently also begun buying shares in the U.S.-listed Chinese electric vehicle maker Xpeng Inc(NYSE:XPEV).Here are some other key Ark Invest trades from Monday:Bought 442,456 shares — estimated to be worth $8.2 million — in Palantir Technologies Inc(NYSE:PLTR). Shares of the Peter Thiel-founded data company closed 1.8% higher at $18.5 a share.Sold 359,577 shares — estimated to be worth $15.3 million — in Twitter Inc(NYSE:TWTR). The micro-blogging company’s stock closed 1.3% lower at $42.7 a share.Bought 345,771 shares — estimated to be worth $6.4 million — in Robinhood Markets Inc(NASDAQ:HOOD). Shares of the commission-free trading app that deals in stocks, exchange-traded funds and cryptocurrencies closed 3.8% higher at $18.4 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008509074,"gmtCreate":1641476369206,"gmtModify":1676533618874,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008509074","repostId":"2201525399","repostType":2,"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008500436,"gmtCreate":1641476359718,"gmtModify":1676533618876,"author":{"id":"3575010414156273","authorId":"3575010414156273","name":"ddb","avatar":"https://static.tigerbbs.com/d2da7c2a149646c953965251f15ea315","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575010414156273","authorIdStr":"3575010414156273"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008500436","repostId":"2201525399","repostType":2,"repost":{"id":"2201525399","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1641419493,"share":"https://ttm.financial/m/news/2201525399?lang=&edition=fundamental","pubTime":"2022-01-06 05:51","market":"us","language":"en","title":"BRIEF-U.S. CDC Says Delivered 618,076,045 Doses Of Covid-19 Vaccine As Of Jan 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2201525399","media":"Reuters","summary":"Jan 5 (Reuters) - U.S. CDC:   * U.S. CDC SAYS DELIVERED 618,076,045 DOSES OF COVID-19 VACCINE AS OF ","content":"<html><body><p>Jan 5 (Reuters) - U.S. CDC:</p><p>   * U.S. CDC SAYS DELIVERED 618,076,045 DOSES OF COVID-19 VACCINE AS OF JAN 5</p><p>   * U.S. CDC SAYS ADMINISTERED 513,839,973 DOSES OF COVID-19 VACCINE AS OF JAN 5 VERSUS 512,665,013 DOSES AS OF JAN 4</p><p>   * U.S. CDC SAYS 245,278,020 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF JAN 5 VERSUS 244,947,293 INDIVIDUALS AS OF JAN 4</p><p>   * U.S. CDC SAYS 206,797,799 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF JAN 5 VERSUS 206,581,659 INDIVIDUALS AS OF JAN 4</p><p>   * U.S. CDC SAYS AS OF JANUARY 5, 72,262,703 PEOPLE RECEIVED A BOOSTER DOSE FOR COVID-19 VACCINE SINCE AUGUST 13, 2021</p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-U.S. CDC Says Delivered 618,076,045 Doses Of Covid-19 Vaccine As Of Jan 5</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-U.S. CDC Says Delivered 618,076,045 Doses Of Covid-19 Vaccine As Of Jan 5\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-06 05:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 5 (Reuters) - U.S. CDC:</p><p>   * U.S. CDC SAYS DELIVERED 618,076,045 DOSES OF COVID-19 VACCINE AS OF JAN 5</p><p>   * U.S. CDC SAYS ADMINISTERED 513,839,973 DOSES OF COVID-19 VACCINE AS OF JAN 5 VERSUS 512,665,013 DOSES AS OF JAN 4</p><p>   * U.S. CDC SAYS 245,278,020 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF JAN 5 VERSUS 244,947,293 INDIVIDUALS AS OF JAN 4</p><p>   * U.S. CDC SAYS 206,797,799 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF JAN 5 VERSUS 206,581,659 INDIVIDUALS AS OF JAN 4</p><p>   * U.S. CDC SAYS AS OF JANUARY 5, 72,262,703 PEOPLE RECEIVED A BOOSTER DOSE FOR COVID-19 VACCINE SINCE AUGUST 13, 2021</p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","MRNA":"Moderna, Inc.","BK4504":"桥水持仓","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201525399","content_text":"Jan 5 (Reuters) - U.S. CDC:   * U.S. CDC SAYS DELIVERED 618,076,045 DOSES OF COVID-19 VACCINE AS OF JAN 5   * U.S. CDC SAYS ADMINISTERED 513,839,973 DOSES OF COVID-19 VACCINE AS OF JAN 5 VERSUS 512,665,013 DOSES AS OF JAN 4   * U.S. CDC SAYS 245,278,020 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF JAN 5 VERSUS 244,947,293 INDIVIDUALS AS OF JAN 4   * U.S. CDC SAYS 206,797,799 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF JAN 5 VERSUS 206,581,659 INDIVIDUALS AS OF JAN 4   * U.S. CDC SAYS AS OF JANUARY 5, 72,262,703 PEOPLE RECEIVED A BOOSTER DOSE FOR COVID-19 VACCINE SINCE AUGUST 13, 2021((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}